Ling Houfu, Zeng Qinghe, Ge Qinwen, Chen Jiali, Yuan Wenhua, Xu Rui, Shi Zhenyu, Xia Hanting, Hu Songfeng, Jin Hongting, Wang Pinger, Tong Peijian
The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Institute of Orthopaedics and Traumatology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Front Pharmacol. 2021 Jun 15;12:678810. doi: 10.3389/fphar.2021.678810. eCollection 2021.
Osteoarthritis (OA) is a common disease characterized by cartilage degeneration. In recent years much attention has been paid to Traditional Chinese Medicine (TCM) since its treatments have shown efficacy for ameliorating cartilage degradation with mild side effects. Osteoking is a TCM prescription that has long been used in OA treatment. However, the exact mechanism of Osteoking are not fully elucidated. In the current study, destabilization of the medial meniscus (DMM)-induced OA mice was introduced as a wild type animal model. After 8 weeks of administration of Osteoking, histomorphometry, OARSI scoring, gait analysis, micro-CT, and immunohistochemical staining for Col2, MMP-13, TGFβRII and pSmad-2 were conducted to evaluate the chondroprotective effects of Osteoking . Further experiments were then performed to detect the effect of Osteoking on chondrocytes. TGFβRII transgenic mice were constructed and introduced in the current study to validate whether Osteoking exerts its anti-OA effects the TGF-β signaling pathway. Results demonstrated that in wild type DMM mice, Osteoking ameliorated OA-phenotype including cartilage degradation, subchondral bone sclerosis, and gait abnormality. Col2, TGFβRII, and pSmad-2 expressions were also found to be up-regulated after Osteoking treatment, while MMP-13 was down-regulated. , the mRNA expression of MMP-13 and ADAMTS5 decreased and the mRNA expression of Aggrecan, COL2, and TGFβRII were up-regulated after the treatment of Osteoking in IL-1β treated chondrocytes. The additional treatment of SB505124 counteracted the positive impact of Osteoking on primary chondrocytes. In TGFβRII mice, spontaneous OA-liked phenotype was observed and treatment of Osteoking failed to reverse the OA spontaneous progression. In conclusion, Osteoking ameliorates OA progression by decelerating cartilage degradation and alleviating subchondral bone sclerosis partly the TGF-β signaling pathway.
骨关节炎(OA)是一种以软骨退变为特征的常见疾病。近年来,由于中医药(TCM)治疗在改善软骨退变方面显示出疗效且副作用较小,因此备受关注。骨克宁是一种长期用于OA治疗的中药方剂。然而,骨克宁的确切作用机制尚未完全阐明。在本研究中,采用内侧半月板不稳定(DMM)诱导的OA小鼠作为野生型动物模型。给予骨克宁8周后,进行组织形态计量学、OARSI评分、步态分析、显微CT以及对Ⅱ型胶原(Col2)、基质金属蛋白酶-13(MMP-13)、转化生长因子β受体Ⅱ(TGFβRII)和磷酸化Smad-2(pSmad-2)的免疫组化染色,以评估骨克宁的软骨保护作用。随后进行进一步实验以检测骨克宁对软骨细胞的影响。本研究构建并引入了TGFβRII转基因小鼠,以验证骨克宁是否通过TGF-β信号通路发挥其抗OA作用。结果表明,在野生型DMM小鼠中,骨克宁改善了OA表型,包括软骨退变、软骨下骨硬化和步态异常。骨克宁治疗后,还发现Col2、TGFβRII和pSmad-2的表达上调,而MMP-13下调。此外,在白细胞介素-1β处理的软骨细胞中,骨克宁治疗后MMP-13和含血小板解聚蛋白样金属蛋白酶5(ADAMTS5)的mRNA表达降低,而聚集蛋白聚糖、COL2和TGFβRII的mRNA表达上调。SB505124的额外处理抵消了骨克宁对原代软骨细胞的积极影响。在TGFβRII小鼠中,观察到自发的OA样表型,骨克宁治疗未能逆转OA的自发进展。总之,骨克宁通过部分经由TGF-β信号通路减缓软骨退变和减轻软骨下骨硬化来改善OA进展。